387 related articles for article (PubMed ID: 21419854)
1. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
[TBL] [Abstract][Full Text] [Related]
2. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
[TBL] [Abstract][Full Text] [Related]
3. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
[TBL] [Abstract][Full Text] [Related]
4. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499.
Chaves AA; Zingaro GJ; Yordy MA; Bustard KA; O'Sullivan S; Galijatovic-Idrizbegovic A; Schuck H; Christian DB; Hoe CM; Briscoe RJ
J Pharmacol Toxicol Methods; 2007; 56(2):103-14. PubMed ID: 17643323
[TBL] [Abstract][Full Text] [Related]
5. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
Nogawa H; Kawai T; Yajima M; Miura M; Ogawa T; Murakami K
Eur J Pharmacol; 2013 Nov; 720(1-3):29-37. PubMed ID: 24211675
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.
Ollerstam A; Visser SA; Duker G; Forsberg T; Persson AH; Nilsson LB; Björkman JA; Gabrielsson J; Al-Saffar A
J Pharmacol Toxicol Methods; 2007; 56(2):131-44. PubMed ID: 17689270
[TBL] [Abstract][Full Text] [Related]
8. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human.
Parkinson J; Visser SA; Jarvis P; Pollard C; Valentin JP; Yates JW; Ewart L
J Pharmacol Toxicol Methods; 2013; 68(3):357-66. PubMed ID: 23567074
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation.
Chaves AA; Keller WJ; O'Sullivan S; Williams MA; Fitzgerald LE; McPherson HE; Goykhman D; Ward PD; Hoe CM; Mixson L; Briscoe RJ
J Pharmacol Toxicol Methods; 2006; 54(2):150-8. PubMed ID: 16679034
[TBL] [Abstract][Full Text] [Related]
10. Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
Carr DB; McDonnell Moorehead T; Bouchard A; Sprenger CR; Hamilton DA; Lang E; Madden D; Lacouture PG; Wright C
Clin Ther; 2013 May; 35(5):646-58. PubMed ID: 23578606
[TBL] [Abstract][Full Text] [Related]
11. Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium.
Holzgrefe H; Ferber G; Champeroux P; Gill M; Honda M; Greiter-Wilke A; Baird T; Meyer O; Saulnier M
J Pharmacol Toxicol Methods; 2014; 69(1):61-101. PubMed ID: 23689033
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Alexandrou AJ; Duncan RS; Sullivan A; Hancox JC; Leishman DJ; Witchel HJ; Leaney JL
Br J Pharmacol; 2006 Apr; 147(8):905-16. PubMed ID: 16474415
[TBL] [Abstract][Full Text] [Related]
13. Left thoracotomy surgical approach for chronic instrumentation in dogs and monkeys providing high-quality electrocardiogram signals.
Henriques TA; Beck TW; Douglas CL; Jones HM; Kremer JJ; Kruzich PJ; Sarazan RD
J Pharmacol Toxicol Methods; 2010; 62(2):136-42. PubMed ID: 20550968
[TBL] [Abstract][Full Text] [Related]
14. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
16. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.
Dubois VF; Casarotto E; Danhof M; Della Pasqua O
Br J Pharmacol; 2016 Oct; 173(19):2819-32. PubMed ID: 27427789
[TBL] [Abstract][Full Text] [Related]
18. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
Ducroq J; Moha ou Maati H; Guilbot S; Dilly S; Laemmel E; Pons-Himbert C; Faivre JF; Bois P; Stücker O; Le Grand M
Br J Pharmacol; 2010 Jan; 159(1):93-101. PubMed ID: 19703166
[TBL] [Abstract][Full Text] [Related]
19. Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.
Chain AS; Dubois VF; Danhof M; Sturkenboom MC; Della Pasqua O;
Br J Clin Pharmacol; 2013 Nov; 76(5):708-24. PubMed ID: 23351036
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
